GSK3862995B

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Chronic Obstructive Pulmonary DiseaseImmunogenicityBronchiectasisPulmonary Disease, Chronic Obstructive

120 competitors in Chronic Obstructive Pulmonary Disease

#DrugCompanyPhaseTrials

1

EXDENSUR

GGlaxo Dba Glaxosmithkline

Phase 3

22

Lunsekimig

Sanofi

Phase 3

33

Tozorakimab

AstraZeneca

Phase 3

24

CM310

KKeymed Biosciences Co.Ltd

Phase 3

15

Sildenafil ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

26

Astegolimab

Roche

Phase 3

37

GSK3862995B

GSK

Phase 2

18

Titrated Oxygen

RRigshospitalet, Denmark

Phase 3

19

Calciferol

Jazz Pharmaceuticals

Preclinical

—10

Duragesic

CCephalon

Preclinical

2Show 29 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Immunogenicity1 trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry

Not yet recruiting·GSK·Phase 1·NCT06979518·30 enrolled

Chronic Obstructive Pulmonary Disease1 trial

A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

Recruiting·GSK·Phase 1·NCT06154837·130 enrolled

Pulmonary Disease, Chronic Obstructive1 trial

A Phase 1, Open-Label, Randomized, Parallel-Group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Two GSK3862995B Formulations After a Single Dose in Healthy Participants

Recruiting·GSK·Phase 1·NCT07789899·24 enrolled

Bronchiectasis1 trial

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Investigate Efficacy, Safety, Immunogenicity, and Pharmacokinetics, of GSK3862995B in Participants With Bronchiectasis

Recruiting·GSK·Phase 2·NCT07201051·363 enrolled

Details

Drug Info

Related News